Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test

• Published in: Oncology letters Vol. 14; no. 5; pp. 6045 - 6052
• Main Authors: Ochiai, Takumi, Nishimura, Kazuhiko, Watanabe, Tomoo, Kitajima, Masayuki, Nakatani, Akinori, Nagayasu, Kiichi, Naito, Shigetoshi, Sato, Tsuyoshi, Kishine, Kenji, Abe, Yu, Hara, Chihiro, Yamada, Susumu, Mashiko, Satomi, Nagaoka, Isao
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.11.2017; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Chemotherapy; Collagen; collagen gel droplet-embedded drug sensitivity test; Colorectal cancer; Development and progression; Drug resistance; Drug therapy; Histograms; individualized chemotherapy; leucovorin and fluorouracil plus irinotecan; leucovorin and fluorouracil plus oxaliplatin; Medical prognosis; Metastasis; Methods; Oncology; Patient outcomes; Patients; Statistical analysis; Testing; leucovorin and fluorouracil plus oxaliplatin; collagen gel droplet-embedded drug sensitivity test; colorectal cancer; individualized chemotherapy; leucovorin and fluorouracil plus irinotecan
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2017.6960

Leucovorin (FOL) and fluorouracil (5-FU) plus oxaliplatin (l-OHP; FOLFOX) or FOL and 5-FU plus irinotecan (SN-38; FOLFIRI) are widely used as first-line chemotherapy regimens in the treatment of advanced colorectal cancer (CRC). However, second-line chemotherapy must be abandoned in certain cases due to disease progression, adverse effects or high medical cost. Therefore, the most effective regimen should be selected as first-line chemotherapy. We reported that individualization of first-line treatment (FOLFOX/FOLFIRI/Dual/Poor responder) was possible using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) and that individualized first-line chemotherapy with CD-DST may improve the prognosis of patients with unresectable CRC. The aim of the present prospective cohort study was to evaluate the individualization of first-line chemotherapy using CD-DST, with a focus on prognosis. Between March 2008 and December 2015, tumor specimens were obtained from 120 patients with CRC who had not received preoperative chemotherapy. CD-DST was performed and the growth inhibition rate (IR) was determined by exposure for 24 h with 5-FU and l-OHP (6.0 and 3.0 µg/ml, respectively) and 5-FU and SN-38 (6.0 and 0.2 µg/ml, respectively). The cumulative distribution of IR values under each condition was evaluated on the basis that the clinical response to FOLFOX and FOLFIRI is equivalent (~50%). The prognosis of dual responder was improved compared with that of poor responders, however this difference was identified to be significant. There was no different prognosis between patients treated with an appropriate first-line regimen and patients treated with an inappropriate first-line regimen in dual responders. However, in poor responders, there were significant differences of prognosis between patients treated with an appropriate first-line regimen and patients treated with an inappropriate first-line regimen (P=0.036). In conclusion, the results from the present study suggest that administration of the recommended first-line regimen using CD-DST for patients with unresectable CRC is important for the improvement of prognosis, particularly in poor responders.